Plasma omentin levels in drug-free patients with schizophrenia

dc.authorid0000-0002-3156-1076en_US
dc.contributor.authorYıldırım, Osman
dc.contributor.authorCanan, Fatih
dc.contributor.authorTosun, Mehrnet
dc.contributor.authorKayka, Nefise
dc.contributor.authorTuman, Taha Can
dc.contributor.authorAlhan, Cafer
dc.contributor.authorAlçelik, Aytekin
dc.date.accessioned2021-06-23T19:36:46Z
dc.date.available2021-06-23T19:36:46Z
dc.date.issued2014
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAims: We aimed to investigate plasma omentin concentrations in non-obese, drug-free patients with schizophrenia in comparison with healthy volunteers. Method:Thirty-two patients with schizophrenia and 33 control subjects were recruited. Plasma omentin levels were determined by enzyme-linked imnnunosorbent assay. Results: Plasma levels of omentin (ng/ml) were found to be markedly lower in patients with schizophrenia (median = 7.7, 25th percentile = 6.3, 75th percentile = 604.9) than in controls (median = 486, 25th percentile = 326, 75th percentile = 794.2, p <0.01). No significant difference was found between drug-free (n = 23) and drug-naive (n = 9) patients with respect to plasma omentin levels. Omentin concentrations correlated negatively with severity of illness, suggesting that patients with more severe pathology had lower fasting levels of omentin (n = 32; r = -0.387; p = 0.029). Conclusion: The present results suggest that plasma omentin levels are decreased in physically healthy, non-obese, antipsychotic-free patients with schizophrenia when compared with physically and mentally healthy individuals. To our knowledge, this is the first study that demonstrated the association between omentin and schizophrenia. 2014 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000360736
dc.identifier.endpage164en_US
dc.identifier.issn0302-282X
dc.identifier.issn1423-0224
dc.identifier.issue3en_US
dc.identifier.pmid24852382en_US
dc.identifier.scopus2-s2.0-84900900155en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage159en_US
dc.identifier.urihttps://doi.org/10.1159/000360736
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8052
dc.identifier.volume69en_US
dc.identifier.wosWOS:000337267300005en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorYıldırım, Osman
dc.institutionauthorTosun, Mehrnet
dc.institutionauthorKayka, Nefise
dc.institutionauthorTuman, Taha Can
dc.institutionauthorAlhan, Cafer
dc.institutionauthorAlçelik, Aytekin
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofNeuropsychobiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdipokinesen_US
dc.subjectOmentinen_US
dc.subjectSchizophreniaen_US
dc.titlePlasma omentin levels in drug-free patients with schizophreniaen_US
dc.typeArticleen_US

Dosyalar